Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.54 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30424046 | 0.87 | DPP3 (0.67) | OPRM1DPP3 | |
| SCHEMBL29498130 | 0.86 | NTSR2 (0.57) | TACR1DPP3 | |
| SCHEMBL30051395 | 0.86 | DPP3 (0.59) | OPRM1DPP3 | |
| SCHEMBL30007955 | 0.86 | NTSR2 (0.65) | TACR1OPRM1KISS1RDPP3 | |
| SCHEMBL30387750 | 0.85 | DPP3 (0.58) | TACR1OPRM1KISS1RDPP3 | |
| SCHEMBL34463652 | 0.85 | OPRM1 (0.57) | TACR1OPRM1KISS1R | |
| SCHEMBL31657596 | 0.85 | NTSR2 (0.61) | TACR1OPRM1DPP3 | |
| SCHEMBL30388268 | 0.85 | OPRM1 (0.63) | TACR1OPRM1KISS1RDPP3 | |
| SCHEMBL31373855 | 0.85 | C5AR1 (0.58) | KISS1R | |
| SCHEMBL29833862 | 0.85 | DPP3 (0.57) | OPRM1KISS1RDPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561963-A | Nicotine acetylcholine receptor peptide antagonist conotoxin compositions and related methods | 格罗制药公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | GLO PHARMA, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-115702161-A | Peptide compositions and methods for inhibiting nicotinic acetylcholine receptor activity | 格罗制药公司 | 2023-02-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076314-A1 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNB1, CHRNG, CHRNA1 | TACR1 68/4885OPRM1 2825/4885KISS1R 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.